ABIOMED INC (ABMD) Stock Fundamental Analysis
USA - NASDAQ:ABMD - US0036541003 - Common Stock
381.02 USD
+0.23 (+0.06%)
381.3 USD
+0.28 (+0.07%)
Taking everything into account, ABMD scores 7 out of 10 in our fundamental rating. ABMD was compared to 189 industry peers in the Health Care Equipment & Supplies industry. ABMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ABMD has a decent growth rate and is not valued too expensively. These ratings could make ABMD a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
In the past year ABMD was profitable.
ABMD had a positive operating cash flow in the past year.
ABMD had positive earnings in each of the past 5 years.
ABMD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 15.72%, ABMD belongs to the top of the industry, outperforming 94.52% of the companies in the same industry.
ABMD has a better Return On Equity (17.32%) than 93.61% of its industry peers.
ABMD's Return On Invested Capital of 12.19% is amongst the best of the industry. ABMD outperforms 89.95% of its industry peers.
ABMD had an Average Return On Invested Capital over the past 3 years of 29.16%. This is significantly above the industry average of 8.99%.
The last Return On Invested Capital (12.19%) for ABMD is well below the 3 year average (29.16%), which needs to be investigated, but indicates that ABMD had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.72% | ||
| ROE | 17.32% | ||
| ROIC | 12.19% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 24.84%, ABMD belongs to the top of the industry, outperforming 95.43% of the companies in the same industry.
ABMD's Profit Margin has improved in the last couple of years.
ABMD's Operating Margin of 23.66% is amongst the best of the industry. ABMD outperforms 93.61% of its industry peers.
ABMD's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.66% | ||
| PM (TTM) | 24.84% | ||
| GM | N/A |
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ABMD is creating value.
Compared to 1 year ago, ABMD has more shares outstanding
ABMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ABMD has an Altman-Z score of 68.47. This indicates that ABMD is financially healthy and has little risk of bankruptcy at the moment.
ABMD has a Altman-Z score of 68.47. This is amongst the best in the industry. ABMD outperforms 99.54% of its industry peers.
There is no outstanding debt for ABMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 68.47 |
ROIC/WACC1.34
WACC9.07%
2.3 Liquidity
A Current Ratio of 7.93 indicates that ABMD has no problem at all paying its short term obligations.
ABMD has a better Current ratio (7.93) than 83.11% of its industry peers.
ABMD has a Quick Ratio of 7.17. This indicates that ABMD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 7.17, ABMD belongs to the best of the industry, outperforming 82.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.93 | ||
| Quick Ratio | 7.17 |
3. Growth
3.1 Past
ABMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
The Earnings Per Share has been growing by 30.92% on average over the past years. This is a very strong growth
ABMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.32%.
The Revenue has been growing by 18.30% on average over the past years. This is quite good.
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS Q2Q%26.21%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Sales Q2Q%7.16%
3.2 Future
Based on estimates for the next years, ABMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.71% on average per year.
The Revenue is expected to grow by 11.13% on average over the next years. This is quite good.
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 78.72, the valuation of ABMD can be described as expensive.
ABMD's Price/Earnings ratio is a bit cheaper when compared to the industry. ABMD is cheaper than 71.69% of the companies in the same industry.
When comparing the Price/Earnings ratio of ABMD to the average of the S&P500 Index (26.34), we can say ABMD is valued expensively.
Based on the Price/Forward Earnings ratio of 66.96, the valuation of ABMD can be described as expensive.
ABMD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ABMD is cheaper than 73.06% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ABMD to the average of the S&P500 Index (34.43), we can say ABMD is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.72 | ||
| Fwd PE | 66.96 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ABMD is valued a bit cheaper than 69.41% of the companies in the same industry.
ABMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ABMD is cheaper than 80.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 79.09 | ||
| EV/EBITDA | 55.82 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ABMD has an outstanding profitability rating, which may justify a higher PE ratio.
ABMD's earnings are expected to grow with 14.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)20.54
PEG (5Y)2.55
EPS Next 2Y9.68%
EPS Next 3Y14%
5. Dividend
5.1 Amount
No dividends for ABMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
381.02
+0.23 (+0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners1.66%
Ins Owner Change0%
Market Cap17.18B
Revenue(TTM)1.07B
Net Income(TTM)266.76M
Analysts70
Price Target375.36 (-1.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.37%
Min EPS beat(2)-5.24%
Max EPS beat(2)15.98%
EPS beat(4)3
Avg EPS beat(4)8.26%
Min EPS beat(4)-5.24%
Max EPS beat(4)15.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-14.37%
Min Revenue beat(2)-16.89%
Max Revenue beat(2)-11.85%
Revenue beat(4)0
Avg Revenue beat(4)-11.39%
Min Revenue beat(4)-16.89%
Max Revenue beat(4)-6.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.09%
PT rev (3m)N/A
EPS NQ rev (1m)4.13%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.46%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-3.26%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.36%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.72 | ||
| Fwd PE | 66.96 | ||
| P/S | 16 | ||
| P/FCF | 79.09 | ||
| P/OCF | 68.45 | ||
| P/B | 11.16 | ||
| P/tB | 12.15 | ||
| EV/EBITDA | 55.82 |
EPS(TTM)4.84
EY1.27%
EPS(NY)5.69
Fwd EY1.49%
FCF(TTM)4.82
FCFY1.26%
OCF(TTM)5.57
OCFY1.46%
SpS23.82
BVpS34.15
TBVpS31.36
PEG (NY)20.54
PEG (5Y)2.55
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.72% | ||
| ROE | 17.32% | ||
| ROCE | N/A | ||
| ROIC | 12.19% | ||
| ROICexc | 25.66% | ||
| ROICexgc | 30.76% | ||
| OM | 23.66% | ||
| PM (TTM) | 24.84% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-10.63%
ROICexgc growth 5Y-2.2%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 122.5% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 81.43% | ||
| Current Ratio | 7.93 | ||
| Quick Ratio | 7.17 | ||
| Altman-Z | 68.47 |
F-Score6
WACC9.07%
ROIC/WACC1.34
Cap/Depr(3y)188.19%
Cap/Depr(5y)276.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)138.14%
Profit Quality(5y)123.31%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS Q2Q%26.21%
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Sales Q2Q%7.16%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%
EBIT growth 1Y-2.58%
EBIT growth 3Y4.52%
EBIT growth 5Y23.29%
EBIT Next Year13.8%
EBIT Next 3Y20.3%
EBIT Next 5Y16.96%
FCF growth 1Y-11.7%
FCF growth 3Y6.24%
FCF growth 5Y31%
OCF growth 1Y-11.94%
OCF growth 3Y4.21%
OCF growth 5Y19.91%
ABIOMED INC / ABMD FAQ
What is the fundamental rating for ABMD stock?
ChartMill assigns a fundamental rating of 6 / 10 to ABMD.
Can you provide the valuation status for ABIOMED INC?
ChartMill assigns a valuation rating of 0 / 10 to ABIOMED INC (ABMD). This can be considered as Overvalued.
Can you provide the profitability details for ABIOMED INC?
ABIOMED INC (ABMD) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for ABMD stock?
The Price/Earnings (PE) ratio for ABIOMED INC (ABMD) is 78.72 and the Price/Book (PB) ratio is 11.16.